Breaking News

Tweet TWEET

Ranbaxy Receives Approval To Market RAN™-Donepezil In Canada

MISSISSAUGA, Ontario, Jan. 7, 2014 /CNW/ - Ranbaxy Pharmaceuticals Canada Inc. 
(RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), 
announced that RPCI received approval on December 24, 2013 to manufacture and 
market RAN™-Donepezil Hydrochloride 5 mg and 10 mg tablets from Health 
Canada.  Total market size of Aricept* (Donepezil Hydrochloride) in Canada is 
$153.9 million ($CAD) [IMS-CDH: November - 2013] and growing at 38% (extended 
units).  Donepezil Hydrochloride is indicated in the treatment of dementia in 
Alzheimer's patients. 
"We are pleased to have gained approval for Donepezil Hydrochloride from 
Health Canada and proud to announce a day one launch!  The finished dosage 
form will be manufactured at Ohm Laboratories located in New Jersey, U.S.A. 
and Ranbaxy anticipates this launch will be beneficial to patients and 
healthcare professionals, as well as a positive economic benefit to the 
healthcare system of Canada," said Paul Drake, President, RPCI. 
Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, 
Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), 
India's largest pharmaceutical company.  RPCI is engaged in the sale and 
distribution of generic prescription products in the Canadian healthcare 
system. 
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an 
integrated, research based, international pharmaceutical company producing a 
wide range of quality, affordable generic medicines, trusted by healthcare 
professionals and patients across geographies. Ranbaxy's continued focus on 
R&D has resulted in several approvals, in developed and emerging markets many 
of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and 
technologies, developed at its own labs. The company has further strengthened 
its focus on generics research and is increasingly working on more complex and 
specialty areas. Ranbaxy serves its customers in over 150 countries and has an 
expanding international portfolio of affiliates, joint ventures and alliances, 
ground operations in 43 countries and manufacturing operations in 8 countries. 
Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic 
in-licensing opportunities and its hybrid business model with Daiichi Sankyo, 
a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is 
introducing many innovator products in markets around the world, where it has 
a strong presence. This is in line with the company's commitment to increase 
penetration and improve access to medicines, across the globe. For more 
information, please visit www.ranbaxy.com. 
*Aricept® is a registered trademark of Pfizer Canada Inc. 
 ___________________________________________________________________
|CONTACTS:|Charles M. Caprariello   |Paul Drake                     |
|_________|_________________________|_______________________________|
|         |Vice President, Corporate|President                      |
|         |Communications           |                               |
|_________|_________________________|_______________________________|
|         |Ranbaxy Inc.             |Ranbaxy Pharmaceuticals Canada,|
|         |                         |Inc.                           |
|_________|_________________________|_______________________________|
|         |(609) 720-5615           |(905) 219-8820                 |
|_________|_________________________|_______________________________|
 

SOURCE  Ranbaxy Pharmaceuticals Canada Inc. 
http://www.ranbaxy.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/January2014/07/c7396.html 
CO: Ranbaxy Pharmaceuticals Canada Inc.
NI: MTC HEA  
-0- Jan/07/2014 15:02 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.